Abstract
Malaria caused by Plasmodium vivax is being diagnosed with increasing frequency in Africa. Some southern countries where it has been detected are Angola, Botswana, Mozambique, Namibia, Zambia and Zimbabwe. Knowing the parasite origin of P. vivax infection recurrences (which can be reinfections, recrudescences or relapses) is important epidemiologically for malaria elimination in Africa. Although hypnozoites will no doubt be a source, we should try to determine how frequently the origin of non-reinfection recurrences of P. vivax malaria involving closely related parasites may be non-circulating merozoites rather than hypnozoites.
Keywords: epidemiology, genotyping, hypnozoite, identity by descent, meiotic sibling, Plasmodium vivax, primaquine, relapse, single-cell sequencing, whole-genome sequencing
Globally, approximately 2.5 billion people are at risk of acquiring Plasmodium vivax infection. Malaria caused by P. vivax is being diagnosed with increasing frequency in Africa.1 Some southern countries where it has been detected are Angola, Botswana, Mozambique, Namibia, Zambia and Zimbabwe.1 Knowing the parasite origin (mosquito or human tissue) of P. vivax infection recurrences (which can be reinfections, recrudescences or relapses) is important epidemiologically for malaria elimination in Africa. A reason is that the efficacy of drugs against parasites might vary according to their location in the body. This necessitates elucidatory research. Although hypnozoites2 will no doubt be a source of recurrences, we should try to determine how frequently the origin of non-reinfection recurrences of P. vivax malaria involving closely related parasites may be non-circulating merozoites rather than hypnozoites.
One reason why this possibility should be considered in P. vivax population genetics studies is the recent discovery that, in chronic infections, sequestered and multiplying extravascular asexual P. vivax parasites occur in vast numbers.3,4,5,6 Very few hepatic hypnozoites will be present and homologous recurrences can be highly suggestive of a clonal merozoite origin.7 That non-circulating merozoites are likely to be the source of many homologous P. vivax malarial recurrences is a theory I proposed in 2011 and 2012 and have advanced incrementally.7,8,9
As has been explained elsewhere,10 a few recent papers have avoided mentioning where the theory arose. This failure to acknowledge such a pertinent and unique contribution (following on from my coining of the term hypnozoite2 which is, unethically, poorly cited) makes those papers defective pieces of scholarship and hence non-authoritative.
This theory regarding the non-hypnozoite, intra-host parasite origin of P. vivax infection recurrences includes not only short-term homologous recurrences but also, for various reasons,8,9,10 long-term recurrences in which the parasites are likewise closely related to those from a pre-recurrence time point. The reliability of the temporal criterion that post-28-day recurrences are more likely to be relapses (these are hypnozoite-mediated) than recrudescences (which, by definition, have a merozoite origin) has been questioned.10 Another way to explain8,9,10 why some long-term homologous recurrences of P. vivax malaria may be recrudescences is by comparing them with long-term homologous recurrences of Plasmodium malariae and Plasmodium falciparum malaria. Those recurrences are thought to be recrudescences because a hypnozoite stage is not known to occur in the life cycle of either P. malariae or P. falciparum. There is no known reason why long-term homologous P. vivax malarial recurrences should not have an equivalent non-hypnozoite origin, at least sometimes.8,9
A drug-associated explanation for apparent relapses has also been put forward. This needs to be followed up. Recurrence patterns in groups of patients treated with the hypnozoitocide primaquine, as well as some results of mathematical modelling, have in the past been interpreted as indicating that most recurrences of P. vivax malaria are relapses. However, the recently elucidated mechanism of action of primaquine suggests that non-circulating merozoites in bone marrow and perhaps elsewhere too can be inactivated by the drug,10 in addition to hypnozoites being killed. If this is so, primaquine might not only reduce the number of subsequent relapses but also prevent an unknown percentage of recrudescences from taking place. This newly recognised possibility10 confuses the issue, making the parasite source of non-reinfection homologous recurrences of P. vivax malaria in individual cases inexplicable.
One of the most recent studies to consider the parasite origin of P. vivax malarial recurrences was a meta-analysis.11 By assuming that primaquine kills hypnozoites but not non-hypnozoite asexual stages, the authors were obliged to conclude that most of these recurrences are relapses. This may or may not be correct. At present, we simply do not know.
Understanding the parasite origin or origins of non-reinfection recurrences of P. vivax malaria has thus become even more difficult than it already was. Nonetheless, genotyping remains fundamental for analysing the results of drug trials and planning the control of malaria.12 The issues discussed above must therefore be taken into account in future molecular epidemiological research and in mathematical modelling of recurrent malaria.
Acknowledgements
Competing interests
The author declares that he has no financial or personal relationships that may have inappropriately influenced him in writing this commentary.
Author’s contributions
M.B.M. is the sole author of the commentary.
Ethical considerations
No ethical clearance was required for this commentary.
Funding information
The author received no financial support for the research, authorship, and/or publication of this commentary.
Data availability
Data sharing is not applicable to this commentary as no new data were created or analysed.
Disclaimer
The views and opinions expressed in this commentary are those of the author and do not necessarily reflect the official policy or position of any affiliated agency of the author.
Footnotes
How to cite this article: Markus MB. Theoretical origin of genetically homologous Plasmodium vivax malarial recurrences. S Afr J Infect Dis. 2022;37(1), a369. https://doi.org/10.4102/sajid.v37i1.369
References
- 1.Quaye IK, Aleksenko L, Oeuvray C, et al. The Pan African Vivax and Ovale Network (PAVON): Refocusing on Plasmodium vivax, ovale and asymptomatic malaria in sub-Saharan Africa. Parasitol Int. 2021;84:102415. 10.1016/j.parint.2021.102415 [DOI] [PubMed] [Google Scholar]
- 2.Markus MB. The malarial hypnozoite. Lancet. 1980;315(8174):936. 10.1016/s0140-6736(80)90871-5 [DOI] [PubMed] [Google Scholar]
- 3.Obaldia N, Meibalan E, Sa JM, et al. Bone marrow is a major parasite reservoir in Plasmodium vivax infection. mBio. 2018;9(3):e00625-18. 10.1128/mBio.00625-18 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Brito MAM, Baro B, Raiol TC, et al. Morphological and transcriptional changes in human bone marrow during natural Plasmodium vivax malaria infections. J Infect Dis. In press 2020. 10.1093/infdis/jiaa177 [DOI] [PMC free article] [PubMed]
- 5.Kho S, Qotrunnada L, Leonardo L, et al. Hidden biomass of intact malaria parasites in the human spleen. New Engl J Med. 2021;384(21):2067–2069. 10.1056/NEJMc2023884 [DOI] [PubMed] [Google Scholar]
- 6.Kho S, Qotrunnada L, Leonardo L, et al. Evaluation of splenic accumulation and colocalization of immature reticulocytes and Plasmodium vivax in asymptomatic malaria: A prospective human splenectomy study. PLoS Med. 2021;18(5):e1003632. 10.1371/journal.pmed.1003632 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Markus MB. Source of homologous parasites in recurrent Plasmodium vivax malaria. J Infect Dis. 2012;206(4):622–623. 10.1093/infdis/jis393 [DOI] [PubMed] [Google Scholar]
- 8.Markus MB. Malaria eradication and the hidden parasite reservoir. Trends Parasitol. 2017;33(7):492–495. 10.1016/j.pt.2017.03.002 [DOI] [PubMed] [Google Scholar]
- 9.Markus MB. Biological concepts in recurrent Plasmodium vivax malaria. Parasitology. 2018;145(13):1765–1771. 10.1017/S003118201800032X [DOI] [PubMed] [Google Scholar]
- 10.Markus MB. Safety and efficacy of tafenoquine for Plasmodium vivax malaria prophylaxis and radical cure: Overview and perspectives. Ther Clin Risk Manag. 2021;17:989–999. 10.2147/TCRM.S269336 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Commons RJ, Simpson JA, Watson J, White NJ, Price RN. Estimating the proportion of Plasmodium vivax recurrences caused by relapse: A systematic review and meta-analysis. Am J Trop Med Hyg. 2020;103(3):1094–1099. 10.4269/ajtmh.20-0186 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Barry AE. Complex infections in vivax malaria: The more you look, the more you find. Trends Parasitol. 2021;37(12):1022–1023. 10.1016/j.pt.2021.10.002 [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data sharing is not applicable to this commentary as no new data were created or analysed.